NEW YORK (GenomeWeb) – Kura Oncology said today that it is collaborating with Foundation Medicine to support patient enrollment for Kura's clinical program for tipifarnib in patients with relapsed and/or refractory HRAS mutant squamous cell carcinoma of the head and neck (SCCHN).

Through this collaboration, Foundation Medicine's SmartTrials Precision Enrollment program will contact physicians treating individuals across the US diagnosed with SCCHN whose tumors harbor HRAS mutations as detected in the course of routine clinical care.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Sep
07
Sponsored by
PerkinElmer

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.

Sep
20
Sponsored by
Ion Torrent

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
26
Sponsored by
PerkinElmer

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).